Pharmaceutical interventions for the management of no-reflow.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  The Journal of invasive cardiology

• Publication date

  2008-07-01

• Fields of study

  Medicine

• Identifiers
  PMID 18599901
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The A3 adenosine receptor: an enigmatic player in cell biology.

  2008cited by this paper
• Heart disease and stroke statistics--2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee.

  2008cited by this paper
• Cerebral vasospasm after subarachnoid hemorrhage: the emerging revolution

  2007cited by this paper
• Post‐infarction treatment with simvastatin reduces myocardial no‐reflow by opening of the KATP channel

  2007cited by this paper
• No-reflow phenomenon and prognosis in patients with acute myocardial infarction

  2006cited by this paper
• Efficacy of intracoronary nicardipine in the treatment of no‐reflow during percutaneous coronary intervention

  2006cited by this paper
• Prospective, randomised, controlled trial to study the effect of intracoronary injection of verapamil and adenosine on coronary blood flow during percutaneous coronary intervention in patients with acute coronary syndromes

  2006cited by this paper
• Pretreatment with simvastatin reduces myocardial no‐reflow by opening mitochondrial KATP channel

  2006cited by this paper
• Intracoronary Administration of Abciximab During Percutaneous Coronary Interventions: Should This Be the Routine and Preferred Approach?

  2006cited by this paper
• Restoration of normal coronary flow with tirofiban by intracoronary administration for no-reflow phenomenon after stent deployment.

  2005cited by this paper
• Antagonism of selectin function attenuates microvascular platelet deposition and platelet-mediated myocardial injury after transient ischemia.

  2005cited by this paper
• Different effects of tirofiban and aspirin plus clopidogrel on myocardial no-reflow in a mini-swine model of acute myocardial infarction and reperfusion

  2005cited by this paper
• Detection of embolic particles with the Doppler guide wire during coronary intervention in patients with acute myocardial infarction: efficacy of distal protection device.

  2005cited by this paper
• Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study.

  2005cited by this paper
• Effects of glycoprotein IIb/IIIa inhibition on microvascular flow after coronary reperfusion. A quantitative myocardial contrast echocardiography study.

  2004cited by this paper
• Effect of combined intracoronary adenosine and nicorandil on no-reflow phenomenon during percutaneous coronary intervention.

  2004cited by this paper
• Treatment of slow/no‐reflow phenomenon with intracoronary nitroprusside injection in primary coronary intervention for acute myocardial infarction

  2004cited by this paper
• Nicorandil improves cardiac function and clinical outcome in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: role of inhibitory effect on reactive oxygen species formation.

  2004cited by this paper
• Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

  2004cited by this paper
• Role of platelets in coronary thrombosis and reperfusion of ischemic myocardium.

  2004cited by this paper
• Impact of tirofiban on angiographic morphologic features of high-burden thrombus formation during direct percutaneous coronary intervention and short-term outcomes.

  2003cited by this paper
• Role of incremental doses of intracoronary adenosine for fractional flow reserve assessment.

  2003cited by this paper
• Effect of the PercuSurge GuardWire device on the integrity of microvasculature and clinical outcomes during primary transradial coronary intervention in acute myocardial infarction.

  2003cited by this paper
• Effects of abciximab on microvascular integrity and left ventricular functional recovery in patients with acute infarction treated by primary coronary angioplasty.

  2003cited by this paper
• Resolution of refractory no‐reflow with intracoronary epinephrine

  2002cited by this paper
• Effect of intracoronary nicorandil administration on preventing no-reflow/slow flow phenomenon during rotational atherectomy.

  2002cited by this paper
• Randomized Trial of a Distal Embolic Protection Device During Percutaneous Intervention of Saphenous Vein Aorto-Coronary Bypass Grafts

  2002cited by this paper
• Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.

  2002cited by this paper
• Intracoronary verapamil for reversal of no‐reflow during coronary angioplasty for acute myocardial infarction

  2002cited by this paper
• Angiographic morphologic features of infarct-related arteries and timely reperfusion in acute myocardial infarction: predictors of slow-flow and no-reflow phenomenon.

  2002cited by this paper
• Treatment of no-reflow phenomenon with verapamil after primary stent deployment during myocardial infarction.

  2002cited by this paper
• Treatment of no-reflow and impaired flow with the nitric oxide donor nitroprusside following percutaneous coronary interventions: initial human clinical experience.

  2001cited by this paper
• Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.

  2001cited by this paper
• Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.

  2001cited by this paper
• Antithrombotic therapy in patients undergoing percutaneous coronary intervention.

  2001cited by this paper
• The coronary no-reflow phenomenon: a review of mechanisms and therapies.

  2001cited by this paper
• Intracoronary adenosine administered during percutaneous intervention in acute myocardial infarction and reduction in the incidence of “no reflow” phenomenon

  2000cited by this paper
• Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction. Observations from the TIMI 14 trial.

  2000cited by this paper
• Effects of intracoronary nicardipine, diltiazem and verapamil on coronary blood flow.

  2000cited by this paper
• Adenosine use during aortocoronary vein graft interventions reverses but does not prevent the slow‐no reflow phenomenon

  2000cited by this paper
• Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction.

  2000cited by this paper
• Reversal of "no reflow" during vein graft stenting using high velocity boluses of intracoronary adenosine.

  1998cited by this paper
• Effect of platelet glycoprotein IIb/IIIa receptor inhibition on distal embolization during percutaneous revascularization of aortocoronary saphenous vein grafts. EPIC Investigators. Evaluation of IIb/IIIa platelet receptor antagonist 7E3 in Preventing Ischemic Complications.

  1997cited by this paper
• Evidence for free radical generation after primary percutaneous transluminal coronary angioplasty recanalization in acute myocardial infarction.

  1996cited by this paper
• Clinical implications of the 'no reflow' phenomenon. A predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction.

  1996cited by this paper
• Coronary thrombi increase PTCA risk. Angioscopy as a clinical tool.

  1996cited by this paper
• Treatment of no-reflow in degenerated saphenous vein graft interventions: comparison of intracoronary verapamil and nitroglycerin.

  1996cited by this paper
• Coronary vasomotion during dynamic exercise: influence of intravenous and intracoronary nicardipine.

  1995cited by this paper
• Features and outcome of no-reflow after percutaneous coronary intervention.

  1995cited by this paper
• Intracoronary diltiazem for microvascular spasm after interventional therapy.

  1995cited by this paper
• Initial and long-term outcome of 83 patients after balloon angioplasty of totally occluded bypass grafts.

  1994cited by this paper
• Incidence and treatment of 'no-reflow' after percutaneous coronary intervention.

  1994cited by this paper
• Lack of Myocardial Perfusion Immediately After Successful Thrombolysis: A Predictor of Poor Recovery of Left Ventricular Function in Anterior Myocardial Infarction

  1992cited by this paper
• Reperfusion induced injury: manifestations, mechanisms, and clinical relevance.

  1992cited by this paper
• Morphologic findings in saphenous veins used as coronary arterial bypass conduits for longer than 1 year: necropsy analysis of 53 patients, 123 saphenous veins, and 1865 five-millimeter segments of veins.

  1990cited by this paper
• Effects of intravenous and intracoronary nicardipine.

  1989cited by this paper
• The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes.

  1989cited by this paper
• A novel potent vasoconstrictor peptide produced by vascular endothelial cells

  1988cited by this paper
• Ultrastructural Evidence of Microvascular Damage and Myocardial Cell Injury After Coronary Artery Occlusion: Which Comes First?

  1980cited by this paper
• The "no-reflow" phenomenon after temporary coronary occlusion in the dog.

  1974cited by this paper

• Pathophysiology of Red Blood Cell Trapping in Ischemic Acute Kidney Injury.

  2023cites this paper
• Hidden in Plain Sight: Does Medullary Red Blood Cell Congestion Provide the Explanation for Ischemic Acute Kidney Injury?

  2022cites this paper
• Lipopolysaccharide Pretreatment Prevents Medullary Vascular Congestion following Renal Ischemia by Limiting Early Reperfusion of the Medullary Circulation

  2022cites this paper
• The effect of predilation on the incidence of the no/slow-reflow phenomenon in patients with acute coronary syndrome with ST segment elevation

  2020cites this paper
• Effect of remote ischaemic preconditioning in patients undergoing complex PCI : the ERIC-PCI trial

  2018cites this paper
• Синдром no-reflow при проведенні перкутанної реперфузії міокарда як наслідок пізньої госпіталізації

  2016cites this paper
• No-Reflow Phoenomenon by Intracoronary Thrombus in Acute Myocardial Infarction

  2016cites this paper
• The nitric oxide donor, S-nitroso human serum albumin, as an adjunct to HTK-N cardioplegia improves protection during cardioplegic arrest after myocardial infarction in rats.

  2015cites this paper
• Intracoronary adenosine administered during aortocoronary vein graft interventions may reduce the incidence of no-reflow phenomenon. A pilot randomised trial.

  2014cites this paper
• Angiography and coronary function, a clinical approach

  2013cites this paper
• Effect of chronic pretreatment of angiotensin-converting receptor blocker on no-reflow phenomenon in patients with acute myocardial infarction undergoing percutaneous coronary intervention.

  2013cites this paper
• Two coronary "orphan" diseases in search of clinical consideration: coronary syndromes x and y.

  2012cites this paper
• Percutaneous Intervention Post Coronary Artery Graft Surgery in Patients with Saphenous Vein Graft Disease – State of the Art

  2012cites this paper
• Transradial Approach for Coronary Interventions: The New Gold Standard for Vascular Access?

  2012cites this paper
• Non-invasive evaluation of myocardial reperfusion by transthoracic Doppler echocardiography and single-photon emission computed tomography in patients with anterior acute myocardial infarction

  2011cites this paper
• Dipyridamole versus verapamil for treatment of no‐reflow during primary angioplasty

  2010cites this paper
• Pharmacotherapy: Intracoronary streptokinase in acute myocardial infarction

  2010cites this paper
• The Use of Intracoronary Sodium Nitroprusside to Treat No-Reflow after Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction

  2010cites this paper
• Device therapy: Defibrillators—a shocking therapy for cardiomyopathy?

  2010cites this paper
• Early versus late ST-segment resolution and clinical outcomes after percutaneous coronary intervention for acute myocardial infarction

  2010cites this paper
• Prevention and treatment of microvascular obstruction-related myocardial injury and coronary no-reflow following percutaneous coronary intervention: a systematic approach.

  2010cites this paper
• [Thrombectomy in the acute myocardial infarction: A success in the fight against incomplete myocardial perfusion].

  2010cites this paper
• Adjunctive Thrombectomy and Distal Protection in Primary Percutaneous Coronary Intervention: Impact on Microvascular Perfusion and Outcomes

  2009cites this paper
• Il fenomeno del no-reflow: significato clinico e aspetti diagnostici e terapeutici

  2009cites this paper
• Drosophila melanogaster innate immunity: an emerging role for peptidoglycan recognition proteins in bacteria detection

  2004cites this paper